These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 11221513)

  • 1. Minimal deviation melanoma. Borderline and intermediate melanocytic neoplasia.
    Reed RJ
    Clin Lab Med; 2000 Dec; 20(4):745-58. PubMed ID: 11221513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Variants of melanoma.
    Reed RJ; Martin P
    Semin Cutan Med Surg; 1997 Jun; 16(2):137-58. PubMed ID: 9220553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Intra-epithelial melanocytic neoplasia (MIN), a new term proposed for dysplastic melanocytic lesions].
    Collina G
    Pathologica; 1997 Apr; 89(2):196-8. PubMed ID: 9411373
    [No Abstract]   [Full Text] [Related]  

  • 4. Borderline and atypical melanocytic lesions.
    Brodell RT; Santa Cruz DJ
    Semin Diagn Pathol; 1985 Feb; 2(1):63-86. PubMed ID: 3916688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dimensionalities: borderline and intermediate melanocytic neoplasia.
    Reed RJ
    Hum Pathol; 1999 May; 30(5):521-4. PubMed ID: 10333220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Minimal deviation melanoma: a histologic variant of cutaneous malignant melanoma in its vertical growth phase.
    Muhlbauer JE; Margolis RJ; Mihm MC; Reed RJ
    J Invest Dermatol; 1983 Jun; 80 Suppl():63s-65s. PubMed ID: 6854057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Theory and practical application of superficial atypical melanocytic proliferations of uncertain significance (SAMPUS) and melanocytic tumours of uncertain malignant potential (MELTUMP) terminology: experience with second opinion consultation.
    Pusiol T; Morichetti D; Piscioli F; Zorzi MG
    Pathologica; 2012 Apr; 104(2):70-7. PubMed ID: 22953503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Melanocytic nevi clinically simulating melanoma.
    Makino E; Uchida T; Matsushita Y; Inaoki M; Fujimoto W
    J Dermatol; 2007 Jan; 34(1):52-5. PubMed ID: 17204102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histopathological characteristics of malignant melanoma affecting mucous membranes: a unifying concept of histogenesis.
    Saida T; Kawachi S; Takata M; Kurita H; Kurashina K; Kageshita T; Tonogi M; Okazaki Y; Yamane GY; Takubo K; Ueyama Y
    Pathology; 2004 Oct; 36(5):404-13. PubMed ID: 15370109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Principles of dermatoscopy of pigmented skin lesions.
    Stolz W; Semmelmayer U; Johow K; Burgdorf WH
    Semin Cutan Med Surg; 2003 Mar; 22(1):9-20. PubMed ID: 12773010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cutaneous melanocytic dysplasia and malignant melanoma. A critical review.
    Kwittken J
    J Med; 1991; 22(1):1-16. PubMed ID: 2072047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Minimal deviation melanoma (halo nevus variant).
    Reed RJ; Webb SV; Clark WH
    Am J Surg Pathol; 1990 Jan; 14(1):53-68. PubMed ID: 2294781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Morphometric analysis of the free stromal cells of nevi and malignant melanomas].
    Nikitin AIu
    Vopr Onkol; 1986; 32(2):15-9. PubMed ID: 3962239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The histopathology of cutaneous malignant melanoma.
    Barnhill RL; Mihm MC
    Semin Diagn Pathol; 1993 Feb; 10(1):47-75. PubMed ID: 8506417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dysplastic melanocytic nevi and prognostically indeterminate nevomelanomatoid proliferations.
    Kim JC; Murphy GF
    Clin Lab Med; 2000 Dec; 20(4):691-712. PubMed ID: 11221510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions.
    Nasr MR; El-Zammar O
    Am J Dermatopathol; 2008 Apr; 30(2):117-22. PubMed ID: 18360113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distribution and colocalization of markers for proliferation, invasion, motility and neoangiogenesis in benign melanocytic naevi and malignant melanomas.
    Fröhlich E; Mack AF; Garbe C; Klessen C
    Br J Dermatol; 2005 Dec; 153(6):1159-65. PubMed ID: 16307652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ki-67 and p53 expression in minimal deviation melanomas as compared with other nevomelanocytic lesions.
    Chorny JA; Barr RJ; Kyshtoobayeva A; Jakowatz J; Reed RJ
    Mod Pathol; 2003 Jun; 16(6):525-9. PubMed ID: 12808056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current diagnostic problems in melanoma pathology.
    Ruiter DJ; van Dijk MC; Ferrier CM
    Semin Cutan Med Surg; 2003 Mar; 22(1):33-41. PubMed ID: 12773012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Minimal deviation and/or naevoid melanoma: is recognition worthwhile? A clinicopathological study of nine cases.
    Stas M; van den Oord JJ; Garmyn M; Degreef H; De Wever I; De Wolf-Peeters C
    Melanoma Res; 2000 Aug; 10(4):371-80. PubMed ID: 10985672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.